| P50 | author | Andreas Trumpp | Q45920296 |
| | Andreas Schneeweiss | Q37074948 |
| | Wilko Weichert | Q40935156 |
| | Markus Wallwiener | Q41603467 |
| P2093 | author name string | Albrecht Stenzinger | |
| | Carsten Denkert | |
| | Markus Wallwiener | |
| | Martina Scharpff | |
| | Hans-Peter Sinn | |
| | Corinna Klein | |
| | Irène Baccelli | |
| | Tim Holland-Letz | |
| | Vanessa Vogel | |
| | Massimo Saini | |
| | Berit Maria Pfitzner | |
| P2860 | cites work | Calreticulin Is the Dominant Pro-Phagocytic Signal on Multiple Human Cancers and Is Counterbalanced by CD47 | Q24561405 |
| | The CD47-SIRPα pathway in cancer immune evasion and potential therapeutic implications | Q24605052 |
| | Antibody therapy targeting the CD47 protein is effective in a model of aggressive metastatic leiomyosarcoma | Q24631455 |
| | The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors | Q24631515 |
| | The basics of epithelial-mesenchymal transition | Q24652992 |
| | Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells | Q24657020 |
| | CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis | Q24658222 |
| | Cancer statistics, 2012 | Q27860574 |
| | Epithelial-mesenchymal transitions in development and disease | Q27860630 |
| | Molecular portraits of human breast tumours | Q28032461 |
| | Met, metastasis, motility and more | Q28235183 |
| | Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits | Q28237197 |
| | Invasive growth: a MET-driven genetic programme for cancer and stem cells | Q28253680 |
| | Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. | Q42434873 |
| | Clinicopathologic features and five years survival analysis in molecular subtypes of breast cancer. | Q42467971 |
| | Therapeutic Antibody Targeting of CD47 Eliminates Human Acute Lymphoblastic Leukemia | Q42616476 |
| | Tissue microarray-based studies of patients with lymph node negative breast carcinoma show that met expression is associated with worse outcome but is not correlated with epidermal growth factor family receptors | Q44389290 |
| | C-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu | Q45083973 |
| | Rationale and design of MARQUEE: a phase III, randomized, double-blind study of tivantinib plus erlotinib versus placebo plus erlotinib in previously treated patients with locally advanced or metastatic, nonsquamous, non-small-cell lung cancer | Q47992122 |
| | Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer. | Q48001140 |
| | Significance of circulating hepatocyte growth factor level as a prognostic indicator in primary breast cancer | Q50897751 |
| | Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis | Q52920858 |
| | The prognostic impact of circulating tumor cells in subtypes of metastatic breast cancer | Q53127630 |
| | Reporting recommendations for tumor marker prognostic studies (REMARK). | Q53268902 |
| | Targeting the HGF/c-Met axis: state of play. | Q54676546 |
| | Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update | Q57130157 |
| | The Met tyrosine kinase receptor in development and cancer | Q28263626 |
| | CD47 is expressed abnormally on hematopoietic cells in myelodysplastic syndrome | Q28290090 |
| | Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up | Q28306437 |
| | The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups | Q29614700 |
| | Cell-surface calreticulin initiates clearance of viable or apoptotic cells through trans-activation of LRP on the phagocyte | Q29615441 |
| | Supervised risk predictor of breast cancer based on intrinsic subtypes | Q29617404 |
| | Circulating tumor cells, disease progression, and survival in metastatic breast cancer | Q29619276 |
| | American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer | Q30494798 |
| | Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data | Q30779447 |
| | Hierarchical clustering analysis of tissue microarray immunostaining data identifies prognostically significant groups of breast carcinoma | Q30965944 |
| | Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma | Q34144940 |
| | Gene-expression signatures in breast cancer | Q34948421 |
| | Cancer micrometastases | Q34978121 |
| | Targeting the HGF/c-MET Pathway in Hepatocellular Carcinoma | Q36093497 |
| | The evolving concept of cancer and metastasis stem cells | Q36145729 |
| | Disruption of SIRPα signaling in macrophages eliminates human acute myeloid leukemia stem cells in xenografts | Q36278046 |
| | cMET and phospho-cMET protein levels in breast cancers and survival outcomes | Q37290053 |
| | CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. | Q37305045 |
| | Metastatic stem cells: sources, niches, and vital pathways | Q37720793 |
| | MET signalling: principles and functions in development, organ regeneration and cancer | Q37811895 |
| | c-MET as a potential therapeutic target and biomarker in cancer | Q37962905 |
| | Programmed cell removal: a new obstacle in the road to developing cancer | Q37967032 |
| | Targeting MET in cancer: rationale and progress | Q37978193 |
| | Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study. | Q38062681 |
| | The emerging role of MET/HGF inhibitors in oncology | Q38085900 |
| | The interaction between signal regulatory protein alpha (SIRPα) and CD47: structure, function, and therapeutic target | Q38161542 |
| | Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer. | Q38409218 |
| | High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses | Q38443265 |
| | Met expression is associated with poor outcome in patients with axillary lymph node negative breast carcinoma | Q38466547 |
| | Expression of c-met is a strong independent prognostic factor in breast carcinoma | Q38472256 |
| | Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay | Q39162225 |
| | Breast cancer-derived bone metastasis can be effectively reduced through specific c-MET inhibitor tivantinib (ARQ 197) and shRNA c-MET knockdown | Q39452760 |
| P433 | issue | 18 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 8147-8160 | |
| P577 | publication date | 2014-09-01 | |
| P1433 | published in | Oncotarget | Q1573155 |
| P1476 | title | Co-expression of MET and CD47 is a novel prognosticator for survival of luminal breast cancer patients | |
| P478 | volume | 5 | |